medigraphic.com
ISSN 2594-1526 (Digital)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2020, Número 3

<< Anterior Siguiente >>

Neumol Cir Torax 2020; 79 (3)


SARS-CoV-2: una revisión bibliográfica de los temas más relevantes y evolución del conocimiento médico sobre la enfermedad

Vargas-Lara AK, Schreiber-Vellnagel V, Ochoa-Hein E, López-Ávila A

Idioma: Español
Referencias bibliográficas: 41
Paginas: 185-196
Archivo PDF: 404.16 Kb.


RESUMEN

Desde diciembre de 2019 el mundo se ha visto afectado por una pandemia causada por el virus SARS-CoV-2, el cual pertenece a la familia de los β-coronavirus, conocidos por su gran capacidad infecciosa, rápida transmisión y por manifestarse clínicamente como un síndrome respiratorio que ha provocado la muerte de más de 300,000 personas a nivel mundial. Este documento fue realizado de marzo a mayo de 2020 con el propósito de informar sobre los temas más relevantes de la enfermedad, antecedentes históricos, morfología viral, fisiopatología, transmisión, manifestaciones clínicas, características clínicas de los pacientes infectados y de los pacientes asintomáticos, período de incubación, pruebas diagnósticas, resultados esperados en las pruebas de laboratorio e imagen, principales complicaciones de la infección, posibles tratamientos, estatus del desarrollo de una vacuna y el uso de plasma convaleciente en el tratamiento, prevención y cuidados personales para evitar la infección y por último, posible reinfección. Además de comparar y verificar la información entre varios artículos sobre cada subtema para tener una perspectiva amplia y completa de los diferentes resultados, hallazgos y opiniones que se han generado hasta el momento sobre COVID-19.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):597-506. Available in: https://doi.org/10.1016/S0140-6736(20)30183-5

  2. Fehr AR, Perlman S. Coronavirus: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23. Available in: https://doi.org/10.1007/978-1-4939-2438-7_1

  3. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. Available in: https://doi.org/10.1186/s40249-020-00646-x

  4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. Available in: https://doi.org/10.1056/nejmoa2001017

  5. Solís A. Confirman primer positivo de coronavirus Covid-19 en México. Forbes Staff [en línea]. 28 febrero 2020. [Fecha de consulta 30 de mayo de 2020] Accesible en: https://www.forbes.com.mx/confirman-el-primer-caso-de-coronavirus-covid-19-en-mexico/

  6. Gobierno de la Ciudad de México. Situación actual Covid-19 CDMX (2020) [en línea]. [Fecha de consulta 30 de mayo de 2020] Accesible en: https://datos.cdmx.gob.mx/pages/covid19/?gclid=CjwKCAjwiMj2BRBFEiwAYfTbCpGrk95qVjrIIZffykcTU-jJYcKJarwfG2jjUTGeWtzlQofxnv3ahxoCheQQAvD_BwE

  7. World Health Organization. Coronavirus (COVID-19) events as they happen [Internet]. [Access date 2020 April 28] Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

  8. Perlman S. Anorher decade, another coronavirus. N Engl J Med. 2020;382(8):760-762. Available in: https://doi.org/10.1056/nejme2001126

  9. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16(3):240-246. Available in: https://doi.org/10.1007/s12519-020-00345-5

  10. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;13(1):11. Available in: https://doi.org/10.1186/s40779-020-00240-0

  11. Guana ME, Bernava JL. Recomendaciones diagnósticas y terapéuticas ante la respuesta inmune trombótica asociada a Covid-19 [en línea]. [Fecha de consulta 1 de mayo de 2020] Accesible en: https://fundacionio.com/wp-content/uploads/2020/04/Si%CC%81ndrome-RITAC.pdf.pdf.pdf.pdf.pdf.pdf.pdf

  12. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID- 19 and the possibility of fecal transmission. Aliment Pharmacol Ther. 2020;51(9):843-851. Available in: https://doi.org/10.1111/apt.15731

  13. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS- CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-1567. Available in: https://doi.org/10.1056/nejmc2004973

  14. Okhuese AV. Estimation of the probability of reinfection with COVID-19 by the susceptible-exposed-infectious-removed-undetectable-susceptible model. JMIR Public Health Surveill. 2020;6(2):e19097. Available in: https://doi.org/10.2196/19097

  15. Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 2020;35(18):e174. Available in: https://doi.org/10.3346/jkms.2020.35.e174

  16. Pérez-Suárez B, Martínez-Menchon T, Cutillas-Marco E. Hallazgos cutáneos en la pandemia de COVID-19 en la Región de Murcia (carta al editor). Med Clin (Barc). 2020;155(1):41-42. Disponible en: https://doi.org/10.1016/j.medcli.2020.05.001

  17. Fu B, Fu X. Clinical characteristics of 11 asymptomatic patients with COVID-19. Med Clin (Barc). 2020;155(2):87-88. Available in: https://doi.org/10.1016/j.medcli.2020.04.013

  18. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. Available in: https://doi.org/10.1016/j.jaut.2020.102433

  19. Gennaro FD, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health. 2020;17(8):2690. Available in: https://doi.org/10.3390/ijerph17082690

  20. Massachusetts General Hospital. 2020 [en línea]. [Fecha de consulta 1 de mayo de 2020]. Accesible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/aspectos-hematol%C3%B3gicos-durante-el-COVID-19.pdf

  21. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng Vincent CC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with Coronavirus 2019 (COVID-19). Clin Infect Dis. 2020: ciaa478. Available in: https://doi.org/10.1093/cid/ciaa478

  22. Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO). 2020 [online]. [Access date 2020 09 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04330690?term=Remdesivir&recrs=ade&cond=COVID&draw=2&rank=6

  23. The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients. 2020 [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04321616?term=Remdesivir&recrs=ade&cond=COVID&draw=2&rank=7

  24. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684. Available in: https://doi.org/10.1016/s0140-6736(20)30361-5

  25. Corticosteroids during Covid-19 Viral pneumonia related to SARS-CoV-2 infection (CORTI-Covid). 2020 [online]. [Access date 2020 Jun 10] Available from: https://clinicaltrials.gov/ct2/show/NCT04344288?term=corticosteroids&cond=COVID-19&draw=2&rank=2

  26. Early Short Cpurse Corticosteroids in COVID-19. 2020 [online]. [Access date 2020 Jun 10] Available from: https://clinicaltrials.gov/ct2/show/study/NCT04374071?term=corticosteroids&cond=COVID-19&draw=2&rank=8

  27. Efficacy and Safety of Corticosteroids in COVID-19. 2020 [online]. [Access date 2020 Jun 10] Available from: https://clinicaltrials.gov/ct2/show/NCT04273321?term=corticosteroids&cond=COVID-19&draw=2&rank=6

  28. Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04377620?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=1

  29. Phase 3 Randomized, Doble-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Assiciated Cytokine Storm (RUXCOVID)(RUXCOVID) [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04362137?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=2

  30. Treatment of SARS Caused by COVID-19 With Ruxolitinib [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04334044?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=3

  31. Study of Ruxolitinib Plus Simvastatina in the Prevention and Treatment of Respiratory Failure of COVID-19. (Ruxo-Sim-20) [online]. [Access date 2020 Jun 09] Available from: https://clinicaltrials.gov/ct2/show/NCT04348695?term=Ruxolitinib&recrs=ade&cond=COVID&draw=2&rank=6

  32. Plested E. Investigating a vaccine against COVID-19. 2020. Available in: https://doi.org/10.1186/ISRCTN90906759

  33. A phase I/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells). Chictr.org.cn. 2020 [online]. [Access date 2020 May 31] Available from: http://www.chictr.org.cn/showproj.aspx?proj=53003

  34. Use of convalescent plasma in the treatment of patients with severe COVID-19 pneumonia. En.irct.ir. 2020 [online]. [Access date 2020 May 31] Available from: https://en.irct.ir/trial/47266

  35. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang G, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38-43. Available in: https://doi.org/10.1093/infdis/jiaa228

  36. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561-1562. Available in: https://doi.org/10.1001/jama.2020.4940

  37. Syal K. COVID-19: Herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020. Available in: https://doi.org/10.1002/jmv.25870

  38. Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol. 2020;127:104358. Available in: https://doi.org/10.1016/j.jcv.2020.104358

  39. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence [published online ahead of print, 2020 Apr 9]. J Med Virol. 2020;10.1002/jmv.25855. Available in: https://doi.org/10.1002/jmv.25855

  40. Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599-606. Available in: https://doi.org/10.1007/s00011-020-01342-0

  41. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020;133(9):1039-1043. Available in: https://doi.org/10.1097/cm9.0000000000000774




2020     |     www.medigraphic.com